Tier 3 — preclinical

Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man

L Borgström, B Kågedal
Biopharm Drug Dispos 1990 11(2):131-136

Bibliography

PubMed
PMID 2328298
DOI
10.1002/bdd.2510110205
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignHuman dose-escalation pharmacokinetic study
ModelHuman
Sample10 healthy subjects
InterventionOral NAC doses of 200 mg, 600 mg and 1,200 mg
DurationAcute dose-comparison pharmacokinetic sampling
EndpointsPlasma NAC; Dose proportionality; Pharmacokinetic parameters

What the study showed, in plain terms

Human dose-ranging study examining whether oral NAC pharmacokinetics change across 200 to 1,200 mg doses.

Key findings

Systemic exposure increased across oral doses, but oral pharmacokinetics are shaped by metabolism and should not be treated as a simple one-to-one reflection of swallowed dose.

What this study can and cannot tell us

Small healthy-volunteer study and acute exposure only.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology